ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "spondylarthropathy and treatment"

  • Abstract Number: 1687 • 2016 ACR/ARHP Annual Meeting

    Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis

    Alice B. Gottlieb1, Laura C. Coates2, Catherine L. Shuler3, Chen-Yen Lin3, Susan R. Moriarty3, Chin H. Lee3 and Philip J Mease4, 1Tufts University School of Medicine, Boston, MA, 2University of Leeds, Leeds, United Kingdom, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: PsA is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. Ixekizumab (IXE) is an IgG4 mAb that binds…
  • Abstract Number: 1688 • 2016 ACR/ARHP Annual Meeting

    Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

    Laura C. Coates1, M. Elaine Husni2, Catherine L. Shuler3, Hilde Carlier3, Chen-Yen Lin3, Jiani Mou3, Chin H. Lee3 and Philip J Mease4, 1University of Leeds, Leeds, United Kingdom, 2Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
  • Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting

    Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

    Alice B. Gottlieb1, M. Elaine Husni2, Catherine L. Shuler3, Russel T. Burge3, Chen-Yen Lin3, Chin H. Lee3 and D Gladman4, 1Tufts University School of Medicine, Boston, MA, 2Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 3Eli Lilly and Company, Indianapolis, IN, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…
  • Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting

    Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis

    Kim Papp1, Alice B. Gottlieb2, Catherine L. Shuler3, Russel T. Burge3, Gregory Cameron3, Lisa Kerr3 and Philip J Mease4, 1K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, 2Tufts University School of Medicine, Boston, MA, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology